CANCERS BRONCHIQUES A PETITES CELLULES

CANCERS BRONCHIQUES A PETITES CELLULES
CHIMIOTHERAPIE ACCELEREE

Référence	chimiothérapie	stade	n pts	RO %	p	SM	p	DIR %	p
Miles, 1994	CDDP-VP16~Ifo-ADR	tous			NS				NS
	1. accéléré+G-CSF		23	74		?		84
	2. accéléré		17	71		?		82
Woll, 1995	VCR-Ifo-CBDCA-VP16	tous			NS		NS		S
	1.accéléré+G-CSF		34	94		69s		134
	2.accéléré		31	93		64s		117
Steward, 1998	CBDCA-VP16-Ifo-VCR	tous			NS		S		ND
	1. accéléré +/- GM-CSF(toutes les 3 s)		147	90		443j		126
	2. non accéléré +/- GM-CSF (toutes les 4 s)		153	77		351j		100
Thatcher, 2000	CPA – ADR – VP16	tous			NS		0,04
	1. toutes les 2 sem + G-CSF		201	79				95
	2. toutes les 3 sem		202	78				85
Woll, 2001	Ifo + Carbo + VP16		50		NS		0,89
	1.standard			76		12m
	2. accélérée + G-CSF			80		12m
Sculier, 2001	Ifo + VDS + épirubicine	ME			0,04		0,86		<0,001
	1. standard		78	59		286 j		93
	2. accéléré + GM-CSF		78	76		264 j		90
	3. accéléré + cotrimoxazole		77	70		264 j		65

Références

(1) Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CW, Spiro SG et al. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994; 12(1):77-82.

(2) Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony- stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995; 13(3):652-659.

(3) Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998; 16(2):642-650.

(4) Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000; 18(2):395-404.

(5) Woll PJ, Thatcher N, Lomax L, Hodgetts J, Lee SM, Burt PA et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 2001; 19(3):712-719.

(6) Sculier JP, Paesmans M, Lecomte J, Van Cutsem O, Lafitte JJ, Berghmans T et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 2001; 85(10):1444-1451.